N/A N=112 Dose Response of Ketorolac in Knee Arthroscopy
Meniscectomy
Primary: PACU Opiate Consumption — 7.7; 6.3; 6.5; 5.0 IV Morphine Equivalents (mg)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=126 A Phase 2a to Evaluate the Safety of MEDI8852 in Adults With Uncomplicated Influenza
Influenza
Primary: Number of Participants With Any Solicited Influenza Symptoms From Day 1 Through Day 10 — 32; 31; 31; 31 Participants
Phase 4 N=300 Wheezing in Black Preterm Infants: Impact of Vitamin D Supplementation Strategy
Wheezing · Allergy
Primary: Number of Infants With Recurrent Wheezing — 42; 56 Participants — p=0.02
N/A N=261 Care Management for the Effective Use of Opioids
Low Back Pain · Pain
Primary: Brief Pain Inventory Total Score at Baseline and Change Score From Baseline at 3, 6, 9, and 12 Months — 6.45; 6.49; 5.41; 5.86 units on a scale — p=0.0385
Phase 2 N=5 BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases
Non Small Cell Lung Cancer With Bone Metastatses
Primary: Number of Symptomatic Skeletal Events (SSE) in Patients Receiving Xofigo With NSCLC and Bone Metastases — 1 Number of participants experiencing SSE
Phase 2 N=155 Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer
Non Squamous Non Small Cell Lung Cancer
Primary: Median Progression-Free Survival — 6; 4.9 months
Phase 4 N=208 Diphenhydramine for Acute Migraine
Migraine
Primary: Number of Participants With Sustained Headache Relief Assessed by Self-evaluation — 40; 38 Participants
Phase 2 N=41 Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor
Hematopoietic/Lymphoid Cancer
Primary: Count of Participants That Experience 1 Year Relapse Free Survival After Undergoing Hematopoietic Stem Cell Transplantation (HSCT) Using the Thomas Jefferson University…
N/A N=76 Methylphenidate (Ritalin) and Memory/Attention in Traumatic Brain Injury (TBI)
Brain Injury
Primary: Neuropsychological Assessment, CVLT-II — 51.3; 51.8; 51.9; 57.2 units on a scale — p=<0.04
Phase 4 N=60 Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DME Trial
Diabetic Macular Edema
Primary: Mean Number of Intravitreal Aflibercept Injections for Subjects Who Were Enrolled and Completed the 3-year VISTA DME (VGFT-OD-1009) Trial — 9.5 injections
N/A N=59 Abortive Treatment of Migraine With the Cefaly® Abortive Program Device
Migraine
Primary: Pain Freedom (PF) at 2 Hours — 17 Participants
Phase 3 N=76 Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature
Idiopathic Short Stature
Primary: Change in Height — 14; 17.1; 18.9 Centimeters — p=<0.006
N/A N=100 Reducing Care-Resistant Behaviors During Oral Hygiene in Persons With Dementia
Care-resistant Behavior · Dementia
Primary: Care-Resistant Behavior — 4.84; 6.3; 4.42; 4.91 units on a scale — p=0.1433
N/A N=238 Personalized Risk Estimator for Rheumatoid Arthritis Family Study
First Degree Relatives of Rheumatoid Arthritis Patients
Primary: Contemplation Ladder — 40; 46; 43; 41 Participants — p=0.043
N/A N=60 EndoMAXX Endoluminal Valve Technology (EVT) Compared to EndoMAXX
Malignant Esophageal Strictures
Primary: Mellow and Pinkas Dysphagia Score at Baseline and 2 Weeks Following the Treatment — 0.6; 0.6 units on a scale